APhA 2025: Navigating Current RSV Vaccination Guidelines and Recommendations
March 23rd 2025Jeff A. Goad, PharmD, MPH, discusses the latest RSV vaccination guidelines and recommendations for 2025, highlighting vaccine options, target populations, timing considerations, evolving CDC policies, and the role of pharmacists in immunization efforts.
Read More
Two pharmacists at the 2025 APhA Annual Meeting debate the role of continuous glucose monitoring (CGM) for non-insulin users, highlighting evolving guidelines, emerging clinical evidence, cost and coverage challenges, and the need for further research to justify widespread adoption.
Read More
APhA 2025: Pharmacists Can Prescribe Contraceptives in 30 States and the District of Columbia
March 22nd 2025Contraceptive options have expanded since 1960, with pharmacists today playing a growing role as prescribers of contraception and studies showing the benefit of pharmacist-driven contraception clinics.
Read More
APhA 2025: A Pharmacist’s Guide to Culturally Competent and Inclusive Care
March 21st 2025Sally Arif, PharmD, BCCP, discusses her presentation on the critical role of pharmacists in addressing health disparities by improving communication, fostering cultural competence, and promoting pharmacoequity.
Watch
Elevated Non-HDL Cholesterol a Stronger Indicator of Major Cardiovascular Events Compared With LDL-C
March 21st 2025Non-high-density lipoprotein cholesterol was found to be more effective at predicting cardiovascular events such as stroke, myocardial outcomes, heart failure, and others compared with low-density lipoprotein cholesterol.
Read More
Experts: Vast Disparities in Opioid Prescribing Observed for Minority Communities in Past Decade
March 21st 2025Allison Ju-Chen Hu, PhD and Yuhua Bao, PhD describe results of their landmark study that found significant differences in opioid prescriptions in racially and ethnically minoritized communities.
Read More
Guselkumab Receives FDA Approval for Adults With Moderately to Severely Active Crohn Disease
March 21st 2025The new indication for guselkumab in Crohn disease builds off a previous approval in ulcerative colitis, providing patients a treatment option for the major forms of inflammatory bowel disease.
Read More